Rao K N, Trehan S, Shetty P A, Noronha J M
Cancer. 1983 Apr 15;51(8):1425-7. doi: 10.1002/1097-0142(19830415)51:8<1425::aid-cncr2820510816>3.0.co;2-8.
We have recently shown that the levels of urinary 6-hydroxymethylpterin are highly elevated (3 to 20 fold) in a variety of human malignancies as compared to its urinary excretion in patients with nonmalignant diseases or normal healthy subjects. In the subsequent studies, this parameter has been shown to be a reliable index for accurately monitoring the response of patients with acute myeloblastic leukemia (AML) during chemotherapy. In this study, the excreted urinary levels of 6-hydroxymethylpterin as well as the bone marrow lymphoblast values were measured simultaneously in four patients with acute lymphoblastic leukemia (ALL) during antileukemic therapy. Various drug regimens employed for treatment have also been indicated. A good correlation was seen between urinary pterin levels and % blasts during treatment, thus accurately monitoring remission or relapse of the disease in response to the antileukemic therapy. These results again conclusively show that the simple noninvasive determination of 6-hydroxymethylpterin provides a reliable index of the total tumor load in acute lymphoblastic leukemic cases undergoing treatment.
我们最近发现，与非恶性疾病患者或正常健康受试者的尿排泄情况相比，多种人类恶性肿瘤患者尿液中6 - 羟甲基蝶呤的水平显著升高（3至20倍）。在随后的研究中，该参数已被证明是准确监测急性髓性白血病（AML）患者化疗反应的可靠指标。在本研究中，对4例急性淋巴细胞白血病（ALL）患者在抗白血病治疗期间同时测定了尿液中6 - 羟甲基蝶呤的排泄水平以及骨髓原始淋巴细胞值。还指出了用于治疗的各种药物方案。治疗期间尿蝶呤水平与原始细胞百分比之间存在良好的相关性，从而准确监测了疾病对抗白血病治疗的缓解或复发情况。这些结果再次确凿地表明，简单的非侵入性测定6 - 羟甲基蝶呤可为接受治疗的急性淋巴细胞白血病病例的总肿瘤负荷提供可靠指标。
